Inside every healthy body, billions of cells follow a simple rule: they divide when they are needed, do their job, and then quietly switch themselves off when their work is done. This balance between cells being born and cells dying keeps our tissues healthy and stops tumours from forming. When the balance breaks, disease can follow.
Histiocytosis is one such disease. For decades, doctors argued about what it really was a cancer, an overactive immune response, or something else entirely. We now know it is a "neoplastic inflammatory" disorder: it behaves partly like a tumour and partly like an immune reaction that will not settle. At its heart is a broken switch that tells certain immune cells to keep living when they should be dying, and to keep stirring up inflammation when the body has had more than enough.
This article explains what scientists now understand about that broken switch, why the imbalance between cell death and cell growth drives the disease, and how this knowledge has transformed treatment in ways that would have seemed like science fiction just fifteen years ago.
What is histiocytosis?
Histiocytosis is a family of rare disorders in which the body produces too many of a specialised type of white blood cell called a histiocyte. Histiocytes are part of the immune system: some clear away debris and germs, while others raise the alarm and recruit further immune cells to fight threats. In a healthy person, these cells patrol the body and die off in controlled numbers. In histiocytosis, they build up inside tissues and organs, where they cause damage and trigger inflammation.
The most common form is Langerhans cell histiocytosis (LCH). Other forms include Erdheim-Chester disease (ECD), which mostly affects adults in late middle age, and Rosai-Dorfman disease. LCH can appear in a single bone or, more rarely, in several organs at once.
The disease is uncommon. It affects roughly 4 to 5 children in every million each year, and around 1 adult in every million. In children it most often appears between the ages of one and three, and is slightly more common in boys. Adult cases are rarer and are sometimes linked to smoking, which can affect the lungs.
Because the disease is rare and shows up in so many different ways stubborn skin rashes, bone pain, unexplained thirst, or breathing problems it is often misdiagnosed at. Understanding the biology behind it has not only sharpened diagnosis but has given doctors targeted treatments that work remarkably well.
Why do the cells build up?
To understand what goes wrong, it helps to know about two normal processes that happen in every cell.
Cell growth (also called proliferation) is the way cells divide and multiply. Every second, your body makes millions of new cells to replace those lost to injury, infection, or everyday wear. Growth is essential, but it must be controlled. Growth that runs out of control is, in essence, what cancer is.
Cell death (also called apoptosis, pronounced ay-pop-TOH-sis) is the cell’s built-in self-destruct mechanism. When a cell is damaged, infected, or simply no longer needed, internal signals trigger a tidy dismantling: the cell shrinks, parcels up its contents, and is quietly cleared away by neighbouring cells. Crucially, this happens without spilling inflammation into the surrounding tissue.
Healthy tissue depends on a balance between the two: cells are born, do their work, and die on schedule. Disease arises when cells either grow too aggressively or refuse to die on time or both.
For decades, doctors assumed histiocytosis was driven mainly by cells growing too fast. The story has turned out to be more interesting. Research now suggests that in many lesions the bigger problem is that the cells fail to die: they are not necessarily dividing wildly, but they refuse to switch themselves off when they should. They linger, build up, and keep calling in more immune cells. The result looks like uncontrolled growth, but the underlying problem is different and that difference matters for treatment.
What keeps the switch stuck "on"?
So what turns a healthy histiocyte into a cell that will not die? The answer lies in a single, well-studied chain of signals inside the cell called the MAPK pathway.
Think of the MAPK pathway as a row of dominoes inside the cell. When the first domino is tipped, each one knocks over the next, eventually delivering a message to the cell’s control centre that says, in effect, "grow, survive, do not die." This is a normal and necessary signal. The problem begins when one of the dominoes gets jammed permanently in the "fallen" position, so the growth-and-survive message never switches off.
In histiocytosis, the most common jammed domino is a gene called BRAF. A single change in its genetic code known as the BRAF V600E mutation locks the BRAF protein into the "on" position. This mutation is found in about half of LCH cases and in around 50 to 75% of ECD cases. Even in patients without the BRAF mutation, the MAPK pathway is still switched on in nearly every case, because other mutations can jam a different domino in the same chain.
This constant "on" signal does several things at once: it blocks the cell’s normal self-destruct machinery, traps the cells in the tissues, and tells them to release a flood of inflammatory chemicals that recruit yet more immune cells to the scene. The result is a self-feeding loop of inflammation. Some of the immune cells that arrive even help shield the abnormal histiocytes from being cleared, creating a kind of protective bubble around the lesion.
Where in the body the mutation first arises seems to shape how severe the disease becomes. When it appears in an early blood-cell precursor, the disease tends to affect many organs and carries a higher risk. When it arises in a more mature cell, the result is usually a single localised lesion in one bone or patch of skin.
Symptoms and diagnosis
Because misguided histiocytes can settle almost anywhere, histiocytosis can mimic dozens of different illnesses. Common signs include persistent bone pain or visible lumps on the skull, stubborn rashes (especially on the scalp and body of infants), unexplained excessive thirst and urination (a sign that the pituitary gland is involved), swollen lymph nodes, breathing difficulties, and when the brain or nervous system is affected changes in behaviour or balance.
In LCH, more than three-quarters of patients have bone involvement. In children the disease most often affects bone, skin, and bone marrow; in adults the lungs are a more frequent site, especially among smokers. ECD typically affects the long bones, heart, large blood vessels, kidneys, and brain in middle-aged and older adults.
Diagnosis requires a tissue biopsy. Under the microscope, pathologists look for specific markers on the surface of the abnormal cells and for the cells’ characteristic appearance. Modern practice adds molecular testing for BRAF and other MAPK-pathway mutations, because the results directly guide treatment. Imaging scans (X-rays, CT, MRI, and PET) map how far the disease has spread and check whether "risk organs" the liver, spleen, and bone marrow — are involved, since involvement of these organs carries a worse outlook.
The outlook varies with this spread. Patients without risk-organ involvement generally have an excellent outlook, while involvement of the risk organs lowers survival considerably. Earlier diagnosis and modern targeted therapy are narrowing this gap.
Treatment
For decades, the main treatment for histiocytosis was chemotherapy, typically a combination of vinblastine and a steroid such as prednisone. This works for many patients, but not all, and it can come with significant side effects.
The real revolution came with targeted therapy. Once researchers understood that many LCH and ECD lesions involve an overactive MAPK pathway, they turned to drugs originally developed for melanoma that block specific points in that chain of dominoes.
Vemurafenib, a BRAF inhibitor, was among the first such drugs tested. The results were striking: a pooled analysis reported responses in around 94% of patients with hard-to-treat LCH, with most responding within weeks. In ECD, vemurafenib produced responses in about 55% of patients and, in 2017, became the first targeted therapy approved by the US Food and Drug Administration for the disease. A second BRAF inhibitor, dabrafenib, has shown a response rate of around 77% in children with BRAF-mutant LCH.
For patients without a BRAF mutation, other drugs called MEK inhibitors such as cobimetinib and trametinib target the next domino in the chain and work whether or not BRAF is mutated. In October 2022, cobimetinib became the first drug approved as a single agent for adult patients with histiocytic neoplasms, including LCH, ECD, and Rosai-Dorfman disease, expanding effective treatment to the many patients who lack a BRAF mutation.
These results are powerful evidence that the imbalance between cell death and cell growth is a major driver in many histiocytosis lesions: turn down the survival signals that keep abnormal cells alive, and lesions often shrink rapidly. It is important to add, though, that these drugs are not always curative; the disease can return after they are stopped, so researchers are still working out the best way to combine, sequence, and time them.
Living with histiocytosis
As treatment has improved, the conversation has shifted from simply surviving to living well afterwards. A large proportion of people treated for multisystem LCH live with long-term effects, which can include hormonal problems (especially diabetes insipidus, where the body cannot regulate water balance), cognitive or memory difficulties, balance and coordination problems, and chronic lung disease. Targeted therapies bring their own challenges: skin rashes, sun sensitivity, and fatigue, and many patients eventually need to adjust or pause treatment.
For patients and families, the practical takeaways are clear:
- Find a specialist centre experienced with histiocytosis, because the disease is rare enough that most doctors see only a case or two in a career
- Ask for molecular testing at diagnosis, since knowing which mutation is present directly shapes the best treatment plan
- Build a long-term follow-up team that may include endocrinology, neurology, and lung specialists, because complications can appear years after the disease is controlled
- Connect with patient organisations, which can link families with specialists, research updates, and others who understand the journey
Histiocytosis remains a serious diagnosis, but the past fifteen years have transformed it from a disease shrouded in mystery into one of the clearest examples of precision medicine at work. Understanding why these immune cells refuse to die did not just satisfy scientific curiosity changed lives.
Further Reading
Understanding Histiocytosis Basics
- National Cancer Institute information on Langerhans Cell Histiocytosis Treatment
- MedlinePlus Genetics overview of Langerhans cell histiocytosis
- StatPearls / NCBI Bookshelf entry on Langerhans Cell Histiocytosis
- Great Ormond Street Hospital condition guide on Langerhans cell histiocytosis
Cell Biology of Apoptosis and Proliferation
- NIH National Cancer Institute educational materials on cell signalling and the cell cycle
- PubMed reviews on the MAPK/ERK signalling pathway
- Cochrane Library entries on targeted cancer therapy mechanisms
Diagnostic Methods and Clinical Standards
- Revised classification of histiocytoses by the Histiocyte Society (PubMed-indexed)
- NICE guidance on rare cancers and specialist commissioning
- NHS Specialised Services pathway documents for rare paediatric cancers
Treatment Options and Recent Advances
- FDA approval summaries for vemurafenib and cobimetinib in histiocytic neoplasms
- PubMed systematic reviews of BRAF and MEK inhibitor efficacy in LCH and ECD
- ClinicalTrials.gov registry of ongoing histiocytosis trials, including ulixertinib and combination protocols
Living with Histiocytosis and Long-Term Care
- Histiocytosis UK service information through the NHS Service Directory
- Mayo Clinic patient resources on rare disease management
NIH/NCI survivorship guidance for paediatric cancer survivorsbecome locked in an immature, partially activated stage of development, neither fully functional nor able to retire gracefully. Others enter what scientists call oncogene-induced senescence: a zombie-like state in which cells stop dividing but stubbornly refuse to die. Worse, these senescent cells secrete a steady stream of inflammatory chemicals that damage surrounding tissue.
References
- Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med. 2018;379(9):856-868. https://pubmed.ncbi.nlm.nih.gov/30157397/
- Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672-2681. https://pubmed.ncbi.nlm.nih.gov/26966089/
- Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923. https://pubmed.ncbi.nlm.nih.gov/20519626/
- Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014;124(20):3198-3201. https://pubmed.ncbi.nlm.nih.gov/25202140/
- Senechal B, Elain G, Jeziorski E, et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med. 2007;4(8):e253. https://pubmed.ncbi.nlm.nih.gov/17696642/
- Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669-683. https://pubmed.ncbi.nlm.nih.gov/24638167/
- Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the VE-BASKET study. JAMA Oncol. 2018;4(3):384-388. https://pubmed.ncbi.nlm.nih.gov/29188284/
- Mohapatra D, Gupta AK, Haldar P, et al. Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): a systematic review and meta-analysis. Pediatr Hematol Oncol. 2023;40(1):86-97. https://pubmed.ncbi.nlm.nih.gov/35616365/
- Goyal G, Heaney ML, Collin M, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020;135(22):1929-1945. https://pubmed.ncbi.nlm.nih.gov/32187362/
- Nanduri VR, Pritchard J, Levitt G, Glaser AW. Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis. Eur J Cancer. 2006;42(15):2563-2569. https://pubmed.ncbi.nlm.nih.gov/16959486/
- Whitlock JA, Geoerger B, Dunkel IJ, et al. Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis. Blood Adv. 2023;7(15):3806-3815. https://pubmed.ncbi.nlm.nih.gov/36884302/
- US Food and Drug Administration. Cotellic (cobimetinib) prescribing information: histiocytic neoplasms indication. Silver Spring (MD): FDA; revised October 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206192s005lbl.pdf
Helpful Resources
- Histiocytosis UK (NHS service directory): https://www.nhs.uk/services/service-directory/histiocytosis-uk/N10977023
- Great Ormond Street Hospital — Langerhans cell histiocytosis: https://www.gosh.nhs.uk/conditions-and-treatments/conditions-we-treat/langerhans-cell-histiocytosis/
- National Cancer Institute — LCH treatment (PDQ): https://www.cancer.gov/types/langerhans
- US FDA — vemurafenib approval for Erdheim-Chester disease: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-granted-approval-vemurafenib-erdheim-chester-disease

